You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

250 Results
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade
Intent: Curative
Jun 2020
Guidelines and Advice
Status: Current
ID: MOTAC-6
Version: 2
Sep 2020
Statistical Reports
Document
Document
Regimen
Cancer Type:
Hematologic, 
Lymphoma - T-cell
Intent: Adjuvant, Curative, Palliative
Funding:
ODB - General Benefit
    dexamethasone
Dec 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative, Curative, Adjuvant
Dec 2020
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Palliative, Curative, Adjuvant
Feb 2021
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Intent: Curative
Funding:
ODB - General Benefit
    procarbazine
Dec 2020
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Dec 2020
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Palliative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced Gastric, Gastroesophageal, or Esophageal Cancer
Sep 2023

Pages